Liverpool ChiroChem

What Liverpool ChiroChem does

Liverpool ChiroChem (LCC) is a UK-based specialist chemistry company founded in 2014, headquartered in Liverpool, that manufactures and supplies chiral building blocks used in pharmaceutical research and biotechnology. Its core capability is automated chiral chemistry — the production of stereochemically defined molecular building blocks — positioned as a leader in this niche with applications spanning drug discovery and materials science. The company's customers are research-oriented pharmaceutical and biotechnology organizations, and following its June 2025 acquisition by XtalPi, its reach explicitly extends across the US, Europe, and Asia.

LCC is a small, focused operation with 11–50 employees, led by co-founder and CEO Paul Colbon and co-founder and CSO Jiwu Ruan, supported by chairman Stephen Parker, CFO Philip Tottey, and business development manager Samuel Kirkwood. Between 2018 and 2021 the company raised approximately $7.46M across four funding rounds from a consistent UK investor syndicate led by Praetura Ventures, Deepbridge Capital, Northern Powerhouse Investment Fund, and NPIF Maven Equity Finance — a funding cadence consistent with a capital-efficient research-services firm rather than a heavily capitalized platform play.

On June 13, 2025, XtalPi announced its strategic acquisition of LCC, combining LCC's automated chiral chemistry platform with XtalPi's AI-driven drug discovery capabilities. The deal is positioned to accelerate chemical space exploration and compound discovery for pharmaceutical and materials applications, while giving LCC access to XtalPi's tri-continental commercial infrastructure. Pre-acquisition revenue and pricing are not publicly disclosed; the business model is consistent with B2B supply of specialist chemistry building blocks to pharma/biotech R&D groups.

Name

Liverpool ChiroChem

Website

https://liverpoolchirochem.com

Company type

Private

Founded year

2014

Operating status

Acquired

Headcount range

11–50 employees

Short description

Liverpool ChiroChem manufactures and supplies automated chiral chemistry building blocks for pharmaceutical and biotechnology research. Founded in 2014 in Liverpool, UK, the company was acquired by XtalPi in June 2025 to accelerate drug and materials discovery across US, Europe, and Asia.

Ownership category

akta.pro rank

Product category

Specialty Chemical Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Chemical Manufacturing (325), Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing (325194)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)

Keywords

• Chiral building blocks
• Pharmaceutical chemistry
• Custom synthesis services
• Specialty chemical intermediates
• Drug discovery compounds

Headquarters

HQ city

Liverpool

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Core offering

Liverpool ChiroChem manufactures and supplies specialist chiral building blocks used in pharmaceutical research and biotechnology. Leveraging automated chiral chemistry, the company accelerates the discovery of novel compounds for drug development and materials science applications across the US, Europe, and Asia markets.

Product overview

Liverpool ChiroChem (LCC) operates as a standalone automated chiral chemistry service provider. The company was acquired by XtalPi in June 2025 to enhance chemical space exploration capabilities. Based on available sources, limited product portfolio details are provided; the company is identified as a leader in automated chiral chemistry serving pharmaceutical and materials science sectors across US, Europe, and Asia markets.

Differentiator

Problem solved

Functional benefit

Products and services

• Liverpool ChiroChem (LCC) Chiral Building Blocks

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• XtalPicoreStrategic or Co-development Partner · 13 June 2025XtalPi announced strategic acquisition of Liverpool ChiroChem (LCC). The merger aims to unlock unprecedented power in chemical space exploration by combining LCC's automated chiral chemistry capabilities with XtalPi's existing platforms. This acquisition enhances pharmaceutical and materials compound discovery across US, Europe, and Asia markets.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Combi-Blocks: Specialty chemistry supplier of screening compounds and building blocks, including chiral and heterocyclic scaffolds, serving pharmaceutical R&D customers globally — direct competitor to LCC in chiral building blocks.
• Enamine: Ukraine-based supplier of building blocks, screening libraries, and custom synthesis services for pharma and agrochemical R&D, with a large catalogue overlapping LCC's chiral and complex small-molecule offerings.
• Bide Pharmatech: China-based supplier of building blocks, intermediates, and chiral compounds for drug discovery, with comparable product breadth and pricing competition to LCC in pharma R&D catalogues.
• Strem Chemicals: Specialty chemicals manufacturer and distributor focused on catalysts, ligands, and organometallics — comparable in serving pharma and materials R&D with niche chiral reagents.
• Asymchem: China-based CDMO with strong capabilities in chiral synthesis, asymmetric catalysis, and complex API development — directly comparable in chiral chemistry services for pharma customers.

Broad incumbents

• Sigma-Aldrich (Merck KGaA): Global life science and specialty chemicals incumbent with a massive catalogue including chiral building blocks and reagents, supplying pharma and academic labs — broader portfolio but overlapping in chiral chemistry.
• WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and manufacturing services with substantial chiral chemistry capability — much larger scale, overlapping in pharma building blocks and intermediates.
• ChemPartner: China-based CRO providing chemistry services including custom synthesis, chiral chemistry, and medicinal chemistry for global pharma — adjacent competitor in discovery chemistry.
• Aurigene Pharmaceutical Services: CRO/CDMO offering custom synthesis, chiral chemistry, and process development for pharma — comparable service offering but with broader drug discovery portfolio than LCC.

Regional players

• BioAscent: Scotland-based CRO offering medicinal chemistry and drug discovery services to European pharma/biotech — comparable in chemistry services but primarily serves European clients.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/chirochem

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liverpool ChiroChem